We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
VAB-6 combination chemotherapy in resected stage II-B testis cancer.
- Authors
Vugrin, Davor; Whitmore, Willet F.; Herr, Harry W.; Sogani, Pramod; Golbey, Robert B.; Vugrin, D; Whitmore, W F Jr; Herr, H W; Sogani, P; Golbey, R B
- Abstract
Twenty-four patients with resected Stage II-B nonseminomatous germ cell tumors of the testis received adjuvant chemotherapy with the modified VAB-6 regimen for one year. Eighteen patients had nodal category N2B and six nodal category N3 (extranodal extension of tumor). Adjuvant VAB-6 started with two four day inductions at approximately four week intervals. Induction was cyclophosphamide 600 mg/m2 IV, vinblastine 4 mg/m2 IV, dactinomycin 1 mg/m2 IV, bleomycin 30 mg IV on day 1, then bleomycin 20 mg/m2/day by continuous 24 hour infusion for three days, and cis-platinum 120 mg/m2 IV on day 4. Maintenance was vinblastine 6 mg/m2 IV and dactinomycin 1 mg/m2 IV every three weeks. Six patients received a third induction but without bleomycin. All 24 patients remain free of disease with a median follow up of 24 months. Myelosuppression was the major toxicity. Four patients received antibiotics for fever during myelosuppression. In one patient, serum creatinine temporarily rose over 2 mg/dl after cis-platinum. VAB-6 is effective in the prevention of recurrences in resected Stage II-B nonseminomatous germ cell tumors. However, the optimal regimen remains to be defined.
- Publication
Cancer (0008543X), 1983, Vol 51, Issue 1, p5
- ISSN
0008-543X
- Publication type
journal article
- DOI
10.1002/1097-0142(19830101)51:1<5::AID-CNCR2820510103>3.0.CO;2-J